Compare BridgeBio Pharma Inc (BBIO) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nomura Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $83.58 (market cap $16.36B), while Nomura Holdings Inc trades at $9.93 (market cap $28.46B). The key difference: Nomura Holdings Inc is the larger of the two by market cap, and Nomura Holdings Inc pays a 3.31% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NMR | |
|---|---|---|
Market Cap | $16.36B | $28.46B |
Sector | Health | Financials |
52-Week High | $90.17 | $10.04 |
52-Week Low | $47.29 | $6.73 |
Enterprise Value | $18.14B | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
Nomura Holdings (NMR) trades at $9.82, down 1.31% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a robust net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst sentiment is mixed, with a 'Hold' consensus but positive momentum coverage in financial media.
The outlook for NMR is supported by fundamental strength in profitability and revenue expansion, though cash flow volatility and rising debt-to-asset ratios pose risks. The stock presents a value opportunity with a P/E of 11.59, but investors should weigh consistent earnings performance against macroeconomic and sector-specific headwinds affecting financial stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
